KC
ORIAU

Kepos Capital’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Kepos Capital’s Portfolio ORIAU Stock Details ORIAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500,000
Closed -$4.96M – 763
2021
Q3 		$4.96M Sell
500,000
-25,000
-5% -$250K 0.33% 112
2021
Q2 		$5.28M Buy
+525,000
New +$5.29M 0.39% 80

Other funds holding ORIAU

JP
JNE Partners London, United Kingdom $243M AUM 2.37% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Kepos Capital's ORIAU Position: Q4 2021 in Review

Kepos Capital sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q4 2021, closing a stake of 500,000 shares — an estimated $4.96M sold.

Kepos Capital first reported a position in ORIAU in Q2 2021 and held it in 2 quarters. The position peaked at $5.28M in Q2 2021. 18 funds tracked by Wall St. Rank hold ORIAU as of Q4 2021.

  • Kepos Capital reported no remaining Orion Biotech Opportunities Corp. Units position as of Q4 2021 after selling out during the quarter.
  • Kepos Capital sold 500,000 Orion Biotech Opportunities Corp. Units shares in Q4 2021, an estimated $4.96M.
  • Kepos Capital first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 2 quarters.
  • Kepos Capital's Orion Biotech Opportunities Corp. Units position peaked at $5.28M in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q4 2021.

Based on Kepos Capital's 13F filing for Q4 2021, filed 14 Feb 2022.